Last Updated on: 27 July, 2024
About the Company - Astec Lifesciences Ltd
Astec Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/1994 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L99999MH1994PLC076236 and registration number is 076236. Currently Company is involved in the business activities of Manufacture of insecticides, rodenticides, fungicides, herbicides. Company’s Total Operating Revenue is Rs. 676.57 Cr. and Equity Capital is Rs. 19.60 Cr. for the Year ended 31/03/2022.
| Management |
|---|
| Name | Position Held |
|---|
| Mr. Nadir B Godrej | Chairman |
| Mr. Ashok V Hiremath | Non Executive Director |
| Mr. Balram Singh Yadav | Non Executive Director |
| Mr. Anurag Roy | Director |
| Dr. Brahma Nand Vyas | Independent Director |
| Mr. R R Govindan | Independent Director |
| Mr. Nandkumar Dhekne | Independent Director |
| Ms. Anjali Gupte | Independent Director |
| Mr. Burjis Nadir Godrej | Non Executive Director |
Basic Stock Data of Astec Lifesciences Ltd
Last Updated: July 26, 2024, 10:59 pm
| Market Cap | 2,510 Cr. |
|---|
| Current Price | 1,283 |
|---|
| High / Low | 1,490/825 |
|---|
| Stock P/E | |
|---|
| Book Value | 188 |
|---|
| Dividend Yield | 0.12 % |
|---|
| ROCE | 4.48 % |
|---|
| ROE | 11.9 % |
|---|
| Face Value | 10.0 |
|---|
| PEG Ratio | 0.00 |
|---|
Data Source: screener.in
Astec Lifesciences Ltd Quarterly Results
| Month | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|
| Sales | 116 | 172 | 129 | 103 | 173 | 272 | 184 | 200 | 117 | 127 | 143 | 111 | 51 |
| Expenses | 100 | 134 | 104 | 81 | 130 | 207 | 159 | 166 | 105 | 122 | 140 | 114 | 69 |
| Operating Profit | 16 | 38 | 25 | 21 | 43 | 65 | 25 | 33 | 12 | 5 | 3 | -3 | -18 |
| OPM % | 13% | 22% | 19% | 21% | 25% | 24% | 14% | 17% | 10% | 4% | 2% | -3% | -36% |
| Other Income | 3 | 2 | 1 | 1 | 2 | 7 | 3 | 4 | 4 | 3 | 2 | 1 | 1 |
| Interest | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 6 | 6 | 6 | 6 |
| Depreciation | 7 | 7 | 7 | 8 | 9 | 11 | 9 | 8 | 9 | 8 | 9 | 9 | 9 |
| Profit before tax | 11 | 32 | 17 | 12 | 33 | 58 | 15 | 25 | 1 | -6 | -11 | -18 | -32 |
| Tax % | 37% | 26% | 26% | 26% | 25% | 26% | 25% | 25% | 31% | 20% | 26% | 24% | 24% |
| Net Profit | 7 | 24 | 13 | 9 | 25 | 43 | 11 | 18 | 1 | -5 | -8 | -13 | -24 |
| EPS in Rs | 3.61 | 12.23 | 6.63 | 4.63 | 12.63 | 21.97 | 5.82 | 9.34 | 0.43 | -2.54 | -4.18 | -6.85 | -12.41 |
Last Updated: July 12, 2024, 11:25 am
Astec Lifesciences Ltd Quarterly Chart
Astec Lifesciences Ltd Profit & Loss
Last Updated: July 10, 2024, 3:12 pm
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|
| Sales | 112 | 174 | 207 | 267 | 233 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 431 |
| Expenses | 97 | 146 | 171 | 213 | 201 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 445 |
| Operating Profit | 16 | 28 | 35 | 54 | 32 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -13 |
| OPM % | 14% | 16% | 17% | 20% | 14% | 21% | 19% | 18% | 16% | 20% | 23% | 12% | -3% |
| Other Income | 1 | 0 | -0 | -16 | 4 | -8 | 12 | 11 | 12 | 8 | 10 | 13 | 6 |
| Interest | 6 | 7 | 9 | 13 | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 |
| Depreciation | 9 | 12 | 15 | 13 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 35 |
| Profit before tax | 2 | 9 | 11 | 13 | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -67 |
| Tax % | 29% | 32% | 22% | -17% | 59% | 33% | 37% | 36% | 23% | 27% | 26% | 27% | |
| Net Profit | 1 | 6 | 9 | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -51 |
| EPS in Rs | 0.81 | 3.30 | 4.68 | 7.60 | 2.55 | 9.80 | 17.87 | 18.28 | 24.28 | 33.21 | 45.85 | 13.04 | -25.98 |
| Dividend Payout % | 62% | 23% | 21% | 16% | 0% | 15% | 8% | 8% | 6% | 5% | 3% | 12% | |
Astec Lifesciences Ltd Profit & Loss Yearly Chart
Astec Lifesciences Ltd Growth
|
| Compounded Sales Growth |
|---|
| 10 Years: | 8% |
| 5 Years: | 1% |
| 3 Years: | -6% |
| TTM: | -27% |
|
| Compounded Profit Growth |
|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -280% |
|
| Stock Price CAGR |
|---|
| 10 Years: | 35% |
| 5 Years: | 32% |
| 3 Years: | -4% |
| 1 Year: | 2% |
|
| Return on Equity |
|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 6% |
| Last Year: | -12% |
Last Updated: July 24, 2024, 6:03 pm
Astec Lifesciences Ltd Balance Sheet
Last Updated: July 10, 2024, 3:12 pm
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 |
|---|
| Equity Capital | 17 | 18 | 19 | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 80 | 87 | 95 | 116 | 99 | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 375 |
| Borrowings | 74 | 73 | 83 | 93 | 127 | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 431 |
| Other Liabilities | 60 | 83 | 88 | 133 | 85 | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 83 |
| Total Liabilities | 231 | 261 | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 909 |
| Fixed Assets | 76 | 121 | 132 | 133 | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 408 |
| CWIP | 44 | 13 | 6 | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 128 |
| Investments | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 100 | 127 | 146 | 216 | 215 | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 374 |
| Total Assets | 231 | 261 | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 909 |
Astec Lifesciences Ltd Reserves and Borrowings Chart
Astec Lifesciences Ltd Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|
| Cash from Operating Activity | 16 | 15 | 7 | -13 | 19 | 65 | 15 | 168 | -8 | 24 | 75 | 10 |
| Cash from Investing Activity | -13 | -19 | -19 | -17 | -18 | -49 | -52 | -74 | -73 | -104 | -113 | -135 |
| Cash from Financing Activity | -2 | 3 | 12 | 31 | -1 | -18 | 37 | -95 | 81 | 80 | 38 | 125 |
| Net Cash Flow | 1 | -1 | -0 | 2 | 1 | -3 | -0 | 0 | 0 | 0 | -0 | 0 |
|
Astec Lifesciences Ltd Financial Efficiency Indicators
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|
| Debtor Days | 131 | 91 | 142 | 126 | 135 | 122 | 103 | 112 | 123 | 148 | 90 | 135 |
| Inventory Days | 145 | 192 | 147 | 177 | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 |
| Days Payable | 132 | 114 | 179 | 169 | 116 | 155 | 83 | 218 | 137 | 179 | 161 | 102 |
| Cash Conversion Cycle | 145 | 168 | 109 | 134 | 152 | 89 | 142 | 25 | 100 | 145 | 197 | 256 |
| Working Capital Days | 122 | 125 | 125 | 142 | 154 | 115 | 147 | 77 | 101 | 163 | 175 | 234 |
| ROCE % | 9% | 11% | 20% | 12% | 20% | 22% | 20% | 20% | 22% | 22% | 8% | |
Astec Lifesciences Ltd Financial Efficiency Indicators Chart
Astec Lifesciences Ltd Share Holding Pattern
| Month | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|
| Promoters | 65.23% | 65.20% | 65.20% | 65.19% | 65.29% | 65.29% | 66.77% | 66.76% | 66.76% | 66.76% | 66.75% | 66.75% |
| FIIs | 0.25% | 0.19% | 0.22% | 0.29% | 0.32% | 0.48% | 1.53% | 2.19% | 2.29% | 1.95% | 1.33% | 1.28% |
| DIIs | 10.67% | 10.93% | 12.21% | 12.74% | 12.56% | 11.79% | 9.82% | 9.57% | 10.58% | 10.15% | 10.16% | 9.74% |
| Public | 23.85% | 23.68% | 22.37% | 21.78% | 21.83% | 22.45% | 21.87% | 21.49% | 20.37% | 21.13% | 21.74% | 22.22% |
| No. of Shareholders | 19,872 | 22,817 | 21,073 | 19,002 | 16,951 | 17,433 | 17,632 | 19,545 | 17,809 | 18,703 | 18,722 | 19,244 |
Astec Lifesciences Ltd Shareholding Pattern Chart
No. of Astec Lifesciences Ltd Shareholders
Astec Lifesciences Ltd Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|
| Nippon India Small Cap Fund | 468,589 | 0.17 | 62.02 | 11,923 | 2024-07-25 | 3830.13% |
| ICICI Prudential Multicap Fund | 457,669 | 0.69 | 60.58 | 11,923 | 2024-07-25 | 3738.54% |
| ICICI Prudential Smallcap Fund | 452,546 | 0.99 | 59.9 | 11,923 | 2024-07-25 | 3695.57% |
| Nippon India Multi Cap Fund | 257,718 | 0.16 | 34.11 | 11,923 | 2024-07-25 | 2061.52% |
| ICICI Prudential Commodities Fund | 112,360 | 1.12 | 14.87 | 11,923 | 2024-07-25 | 842.38% |
| ICICI Prudential MidCap Fund | 15,844 | 0.05 | 2.1 | 11,923 | 2024-07-25 | 32.89% |
| ITI Value Fund | 11,923 | 1.13 | 1.58 | 11,923 | 2024-07-25 | 0% |
| ITI Pharma and Healthcare Fund | 11,754 | 1.15 | 1.56 | 11,923 | 2024-07-25 | -1.42% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 5,371 | 0.18 | 0.71 | 11,923 | 2024-07-25 | -54.95% |
Astec Lifesciences Ltd ROCE Trend
Astec Lifesciences Ltd EPS Trend
Astec Lifesciences Ltd Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -23.93 | 13.04 | 45.87 | 33.23 | 24.29 |
| Diluted EPS (Rs.) | -23.93 | 13.04 | 45.85 | 33.21 | 24.27 |
| Cash EPS (Rs.) | -5.42 | 30.22 | 63.39 | 46.32 | 36.13 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 188.44 | 214.00 | 202.40 | 157.91 | 126.17 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 188.44 | 214.00 | 202.40 | 157.91 | 126.17 |
| Revenue From Operations / Share (Rs.) | 233.66 | 320.40 | 345.23 | 283.28 | 267.07 |
| PBDIT / Share (Rs.) | -0.13 | 45.56 | 83.96 | 61.00 | 49.63 |
| PBIT / Share (Rs.) | -18.62 | 28.39 | 66.43 | 47.90 | 37.79 |
| PBT / Share (Rs.) | -31.49 | 17.82 | 61.81 | 45.47 | 31.35 |
| Net Profit / Share (Rs.) | -23.91 | 13.05 | 45.86 | 33.22 | 24.29 |
| NP After MI And SOA / Share (Rs.) | -23.93 | 13.04 | 45.85 | 33.21 | 24.28 |
| PBDIT Margin (%) | -0.05 | 14.21 | 24.31 | 21.53 | 18.58 |
| PBIT Margin (%) | -7.97 | 8.86 | 19.24 | 16.90 | 14.14 |
| PBT Margin (%) | -13.47 | 5.56 | 17.90 | 16.05 | 11.73 |
| Net Profit Margin (%) | -10.23 | 4.07 | 13.28 | 11.72 | 9.09 |
| NP After MI And SOA Margin (%) | -10.24 | 4.06 | 13.28 | 11.72 | 9.09 |
| Return on Networth / Equity (%) | -12.70 | 6.09 | 22.66 | 21.03 | 19.26 |
| Return on Capital Employeed (%) | -6.32 | 12.28 | 32.05 | 26.40 | 29.18 |
| Return On Assets (%) | -4.81 | 2.61 | 10.02 | 9.60 | 8.31 |
| Long Term Debt / Equity (X) | 0.53 | 0.02 | 0.00 | 0.12 | 0.00 |
| Total Debt / Equity (X) | 1.34 | 0.81 | 0.70 | 0.60 | 0.40 |
| Asset Turnover Ratio (%) | 0.46 | 0.66 | 0.85 | 0.88 | 1.01 |
| Current Ratio (X) | 1.00 | 0.94 | 1.05 | 1.03 | 1.04 |
| Quick Ratio (X) | 0.51 | 0.38 | 0.67 | 0.69 | 0.66 |
| Inventory Turnover Ratio (X) | 1.30 | 1.91 | 3.04 | 3.03 | 3.12 |
| Dividend Payout Ratio (NP) (%) | -6.26 | 11.50 | 3.26 | 4.51 | 6.17 |
| Dividend Payout Ratio (CP) (%) | -27.54 | 4.96 | 2.36 | 3.23 | 4.15 |
| Earning Retention Ratio (%) | 106.26 | 88.50 | 96.74 | 95.49 | 93.83 |
| Cash Earning Retention Ratio (%) | 127.54 | 95.04 | 97.64 | 96.77 | 95.85 |
| Interest Coverage Ratio (X) | -0.01 | 4.31 | 18.17 | 25.15 | 7.71 |
| Interest Coverage Ratio (Post Tax) (X) | -0.85 | 2.24 | 10.92 | 14.69 | 4.77 |
| Enterprise Value (Cr.) | 2574.29 | 3049.60 | 3711.79 | 2144.94 | 880.19 |
| EV / Net Operating Revenue (X) | 5.62 | 4.85 | 5.49 | 3.87 | 1.68 |
| EV / EBITDA (X) | -9580.53 | 34.14 | 22.56 | 17.95 | 9.06 |
| MarketCap / Net Operating Revenue (X) | 4.55 | 4.31 | 5.08 | 3.53 | 1.50 |
| Retention Ratios (%) | 106.26 | 88.49 | 96.73 | 95.48 | 93.82 |
| Price / BV (X) | 5.64 | 6.46 | 8.66 | 6.34 | 3.17 |
| Price / Net Operating Revenue (X) | 4.55 | 4.31 | 5.08 | 3.53 | 1.50 |
| EarningsYield | -0.02 | 0.01 | 0.02 | 0.03 | 0.06 |
Astec Lifesciences Ltd Profitability Ratios (%)
Astec Lifesciences Ltd Liquidity Ratios
Astec Lifesciences Ltd Liquidity Ratios (%)
Astec Lifesciences Ltd Interest Coverage Ratios (%)
Astec Lifesciences Ltd Valuation Ratios
Strength and Weakness of Astec Lifesciences Ltd Stock
| Strength | Weakness |
|---|
- The stock has a high average ROCE of 15.50%, which is a positive sign.
- The company has higher reserves (207.75 cr) compared to borrowings (183.67 cr), indicating strong financial stability.
- The company has shown consistent growth in sales (377.31 cr) and profit (32.85 cr) over the years.
| - The stock has a high average Working Capital Days of 140.00, which may not be favorable.
- The stock has a high average Cash Conversion Cycle of 138.50, which may not be favorable.
|
FAQ
What is the latest fair value of Astec Lifesciences Ltd?
The latest fair value of Astec Lifesciences Ltd is ₹0.00.
What is the Market Cap of Astec Lifesciences Ltd?
The Market Cap of Astec Lifesciences Ltd is 2,510 Cr..
What is the current Stock Price of Astec Lifesciences Ltd as on 27 July 2024?
The current stock price of Astec Lifesciences Ltd as on 27 July 2024 is 1,283.
What is the High / Low of Astec Lifesciences Ltd stocks in FY 2024?
In FY 2024, the High / Low of Astec Lifesciences Ltd stocks is 1,490/825.
What is the Stock P/E of Astec Lifesciences Ltd?
The Stock P/E of Astec Lifesciences Ltd is .
What is the Book Value of Astec Lifesciences Ltd?
The Book Value of Astec Lifesciences Ltd is 188.
What is the Dividend Yield of Astec Lifesciences Ltd?
The Dividend Yield of Astec Lifesciences Ltd is 0.12 %.
What is the ROCE of Astec Lifesciences Ltd?
The ROCE of Astec Lifesciences Ltd is 4.48 %.
What is the ROE of Astec Lifesciences Ltd?
The ROE of Astec Lifesciences Ltd is 11.9 %.
What is the Face Value of Astec Lifesciences Ltd?
The Face Value of Astec Lifesciences Ltd is 10.0.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a
SEBI registered financial advisor and does not have any vested interest in Astec Lifesciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source:
NSE 
